NASDAQ: CMMB
Chemomab Therapeutics Ltd Stock Ownership - Who owns Chemomab Therapeutics?

Insider buying vs selling

Have Chemomab Therapeutics Ltd insiders been buying or selling?

No trades
There has been no insiders buying vs selling in the past 12 months.

Be the first to know when CMMB insiders and whales buy or sell their stock.

CMMB Shareholders

What type of owners hold Chemomab Therapeutics Ltd stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Access Industries Holdings LLC1.83%6,911,166$8.02MInsider
Gabriel Capital Management Ltd1.33%5,034,150$5.84MInsider
Orbimed Israel GP Ltd0.59%2,241,274$2.60MInsider
Orbimed Advisors LLC0.46%1,741,273$2.02MInstitution
George Adi Mor0.36%1,339,964$1.55MInsider
Sphera Funds Management Ltd0.32%1,214,575$1.41MInstitution
Peter Thiel0.23%877,973$1.02MInsider
Yelin Lapidot Holdings Management Ltd0.20%744,127$863.19kInstitution
Dennison T. Veru0.11%396,540$459.99kInsider
Ikarian Capital LLC0.06%213,052$247.14kInstitution

1 of 3

CMMB vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
CMMB1.10%4.49%
ELEV67.50%20.02%Net SellingNet Selling
PASG44.69%55.31%Net SellingNet Selling
CDIO4.93%14.55%Net Buying
IGC3.56%23.32%Net Buying

Chemomab Therapeutics Stock Ownership FAQ

Who owns Chemomab Therapeutics?

Chemomab Therapeutics (NASDAQ: CMMB) is owned by 1.10% institutional shareholders, 4.49% Chemomab Therapeutics insiders, and 94.41% retail investors. Access Industries Holdings LLC is the largest individual Chemomab Therapeutics shareholder, owning 6.91M shares representing 1.83% of the company. Access Industries Holdings LLC's Chemomab Therapeutics shares are currently valued at $8.09M.

If you're new to stock investing, here's how to buy Chemomab Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.